US Cancer Biomarkers Market Opportunities, Industry 2031
US Cancer Biomarkers Market Opportunities, Industry 2031
Segments - United States Cancer Biomarkers Market by Diseases (Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, and Others), Types (Protein Biomarkers, Genetic Biomarkers, and Others), Profiling Technologies (OMICS Technology, Imaging Technology, Immunoassays, and Cytogenetic), and Country - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 –2031
Upcoming
| Report ID :HC-3963
| 4.5 Rating
| 76 Reviews
| 202 Pages
| Format :
Report Description
United States Cancer Biomarkers Market Outlook
The United States Cancer Biomarkers Market size was valued at USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031 expanding at a CAGR of 11.2% during 2023 – 2031. The growth of the market is attributed to increasing prevalence of cancer and changing lifestyle.
Around 19.3 million people suffer from cancer in the world and in the US, and approximately 1.8 million cases were alone found in 2020. Cancer biomarkers are molecules that show the existing of cancerous cells in the body.
It can be found in the blood, stool, urine, tumor tissue, or other tissues. Various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids are available. These biomarkers are used as diagnostics, prognostics, and surrogate endpoints.
United States Cancer Biomarkers Market Trends, Drivers, Restraints, and Opportunities
- Increasing geriatric population is projected to boost the market growth in the coming years.
- Rising lifestyle disorders and consumption of drugs and alcohol is anticipated to drive the market growth during the forecast period.
- Increasing technological advancements is expected to spur the market growth during the forecast period.
- Growing patient assistance programs is projected to boost the market growth in the coming years.
- A government initiative to control the cancer diseases and policies in favor of the industry is expected to spur the market growth during the forecast period.
- Proving clinical validity and utility of biomarker-based tests can create challenges for the market growth.
- High cost of medicines is estimated to restrict the market growth in the coming years.
- Increasing demand for personalized medicine can create lucrative opportunities during the forecast period.
Scope of United States Cancer Biomarkers Market Report
The report on the United States cancer biomarkers market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Cancer Biomarkers Market - United States Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Diseases (Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer and Others), Types (Protein Biomarkers, Genetic Biomarkers, and Others), and Profiling Technologies (OMICS Technology, Imaging Technology, Immunoassays, and Cytogenetic) |
|
Country |
The US |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Abbott Laboratories Inc.; Agilent Technologie; Biomerieux; F. Hoffmann-La Roche Lt; Hologic Inc.; Illumina Inc.; and Thermo Fisher Scientific |
United States Cancer Biomarkers Market Segment Insights
Breast cancer segment to hold a significant market share
On the basis of diseases, the United States cancer biomarkers market is divided into prostate cancer, breast cancer, lung cancer, colorectal cancer and others. The lung cancer segment is expected to represent a key share of the market in the coming years due to increasing air pollution in the country, which is a major risk factor for lung cancer.
However, the breast cancer segment is anticipated to expand at a rapid pace during the forecast period owing to the adoption of unhealthy lifestyle, genetic profile of patients, growth in female geriatric population, and exposure to harmful radiations.
Protein biomarkers segment is expected to grow at a rapid pace
Based on types, the United States cancer biomarkers market is segregated into protein biomarkers, genetic biomarkers, and others. The genetic biomarkers segment is anticipated to hold a key share of the market in the coming years due to use of advance technologies for mutation detection. On the other hand, the protein biomarkers segment is anticipated to expand at a rapid pace during the forecast period owing to use of targets for therapeutic treatments.
OMICS technology is estimated to hold a major market share
On the basis of profiling technologies, the United States cancer biomarkers market is segregated into OMICS technology, imaging technology, immunoassays, and cytogenetic. The imaging technology segment is expected to represent a key share of the market in the coming years due to its efficiency in early diagnosis of cancer. On the other hand, the OMICS technology segment is anticipated to expand at a rapid pace during the forecast period owing to reduced cost in genome sequencing.
Segments
The United States cancer biomarkers market has been segmented on the basis of
Diseases
- Prostate Cancer
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Others
Types
- Protein Biomarkers
- Genetic Biomarkers
- Others
Profiling Technologies
- OMICS Technology
- Imaging Technology
- Immunoassays
- Cytogenetic
Country
- The US
Key Players
- Abbott Laboratories Inc.
- Agilent Technologie
- Biomerieux
- F. Hoffmann-La Roche Lt
- Hologic Inc.
- Illumina Inc.
- Thermo Fisher Scientific
Competitive Landscape
Key players competing in the United States cancer biomarkers market includes Abbott Laboratories Inc.; Agilent Technologie; Biomerieux; F. Hoffmann-La Roche Lt; Hologic Inc.; Illumina Inc.; and Thermo Fisher Scientific.
Some of these players are engaging in business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market share.
Frequently Asked Questions
The report covers historic data from 2016 to 2021 and provides forecasts for the period 2023 to 2031.
Major companies covered in the report include Abbott Laboratories Inc., Agilent Technologies, Biomerieux, F. Hoffmann-La Roche Ltd, Hologic Inc., Illumina Inc., and Thermo Fisher Scientific.
There is increasing demand for personalized medicine, which creates lucrative opportunities for market growth during the forecast period.
Challenges include proving the clinical validity and utility of biomarker-based tests and the high cost of medicines, which may restrict market growth.
Profiling technologies include OMICS technology, imaging technology, immunoassays, and cytogenetic. OMICS technology is anticipated to expand rapidly due to reduced genome sequencing costs, while imaging technology is efficient for early cancer diagnosis.
The main types include protein biomarkers, genetic biomarkers, and others. Protein biomarkers are expected to grow rapidly due to their use in therapeutic treatments, while genetic biomarkers hold a significant market share due to advanced mutation detection technologies.
The market is segmented by diseases such as prostate cancer, breast cancer, lung cancer, colorectal cancer, and others. Lung cancer holds a key share due to rising air pollution, while breast cancer is expected to grow rapidly due to lifestyle changes and an aging female population.
Key drivers include the increasing prevalence of cancer, rising geriatric population, lifestyle disorders, technological advancements, growing patient assistance programs, and supportive government initiatives.
Cancer biomarkers are molecules that indicate the presence of cancerous cells in the body. They can be found in blood, stool, urine, tumor tissue, or other tissues and are used for diagnostics, prognostics, and as surrogate endpoints in cancer management.
The United States cancer biomarkers market was valued at USD XX Billion in 2022 and is expected to reach USD XX Billion by 2031, expanding at a CAGR of 11.2% from 2023 to 2031.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Cancer Biomarkers Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cancer Biomarkers Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cancer Biomarkers Market - Supply Chain
4.5. Global Cancer Biomarkers Market Forecast
4.5.1. Cancer Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cancer Biomarkers Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Cancer Biomarkers Market Absolute $ Opportunity
5. Global Cancer Biomarkers Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Cancer Biomarkers Market Size and Volume Forecast by Types
5.3.1. Protein Biomarkers
5.3.2. Genetic Biomarkers
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Cancer Biomarkers Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Cancer Biomarkers Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Cancer Biomarkers Demand Share Forecast, 2019-2026
7. North America Cancer Biomarkers Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Cancer Biomarkers Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Cancer Biomarkers Market Size and Volume Forecast by Types
7.4.1. Protein Biomarkers
7.4.2. Genetic Biomarkers
7.4.3. Others
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Cancer Biomarkers Demand Share Forecast, 2019-2026
8. Latin America Cancer Biomarkers Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Cancer Biomarkers Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Cancer Biomarkers Market Size and Volume Forecast by Types
8.4.1. Protein Biomarkers
8.4.2. Genetic Biomarkers
8.4.3. Others
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Cancer Biomarkers Demand Share Forecast, 2019-2026
9. Europe Cancer Biomarkers Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Cancer Biomarkers Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Cancer Biomarkers Market Size and Volume Forecast by Types
9.4.1. Protein Biomarkers
9.4.2. Genetic Biomarkers
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Cancer Biomarkers Demand Share Forecast, 2019-2026
10. Asia Pacific Cancer Biomarkers Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Cancer Biomarkers Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Cancer Biomarkers Market Size and Volume Forecast by Types
10.4.1. Protein Biomarkers
10.4.2. Genetic Biomarkers
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Cancer Biomarkers Demand Share Forecast, 2019-2026
11. Middle East & Africa Cancer Biomarkers Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Cancer Biomarkers Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Cancer Biomarkers Market Size and Volume Forecast by Types
11.4.1. Protein Biomarkers
11.4.2. Genetic Biomarkers
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Cancer Biomarkers Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Cancer Biomarkers Market: Market Share Analysis
12.2. Cancer Biomarkers Distributors and Customers
12.3. Cancer Biomarkers Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Abbott Laboratories Inc.
12.4.2. Agilent Technologie
12.4.3. Biomerieux
12.4.4. F. Hoffmann-La Roche Lt
12.4.5. Hologic Inc.
12.4.6. Illumina Inc.
12.4.7. Thermo Fisher Scientific
Methodology
Related Reports
Some other reports from this category!
Our Clients
